BioCryst Pharmaceuticals
BCRX
BCRX
117 hedge funds and large institutions have $568M invested in BioCryst Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
5.05% more ownership
Funds ownership: 79.16% → 84.22% (+5.1%)
4% more funds holding
Funds holding: 112 → 117 (+5)
Holders
117
Holding in Top 10
8
Calls
$14.8M
Puts
$2.67M
Top Buyers
| 1 | +$50.4M | |
| 2 | +$22.3M | |
| 3 | +$13.9M | |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$9.06M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$6.47M |
Top Sellers
| 1 | -$8.42M | |
| 2 | -$5.21M | |
| 3 | -$4.45M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.47M |